Whales with a lot of money to spend have taken a noticeably bearish stance on Oscar Health. Looking at options history for Oscar Health OSCR we detected 33 trades. If we consider the specifics of each trade, it is accurate to state that 27% of the investors opened trades with bullish ...

Investors with a lot of money to spend have taken a bearish stance on Twilio TWLO. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

Investors with a lot of money to spend have taken a bullish stance on Samsara IOT. We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.

NEW YORK, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.

Biogen secures rights to commercialize zorevunersen outside North America, while Stoke leads global development and retains U.S. rights. Stoke receives $165 million upfront, up to $385 million in milestones, and royalties, with a Phase 3 trial set to begin in Q2 2025.

Washington, DC, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- The New Civil Liberties Alliance has filed an amicus curiae brief in Federal Communications Commission v. Consumers' Research before the U.S. Supreme Court.

Target Hospitality will construct and provide full turnkey support for the Workforce Hub. Target Hospitality expects $68 million of committed minimum revenue to be realized in 2025. Get real-time earnings alerts before the market moves and access expert analysis that uncovers hidden ...

New fair value accounting rules will improve transparency for companies holding Bitcoin, making it a more viable treasury asset. Saylor attributes Bitcoin's rally to ETF anticipation, monetary policy shifts, and the upcoming halving, which will reduce new supply.

Genuine Parts just turned its good news into bad.

Moderna posted a Q4 EPS loss of $ ( 2.91 ) , missing estimates, while revenue fell to $966M from $2.81B but beat the $942.8M consensus Moderna's norovirus vaccine trial is on FDA hold due to a Guillain-Barré syndrome case but expects no impact on efficacy readout timing.